Efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS) in cyclosporine microemulsion based regimen in de novo living donor kidney transplant recipients; a prospective, open label, multi-center study.

Trial Profile

Efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS) in cyclosporine microemulsion based regimen in de novo living donor kidney transplant recipients; a prospective, open label, multi-center study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Mycophenolate sodium (Primary) ; Ciclosporin; Corticosteroids
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Nov 2011 Actual end date (February 2007) added as reported by ClinicalTrials.gov.
    • 09 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top